Monica Forbes - Mar 2, 2023 Form 4 Insider Report for Sesen Bio, Inc. (CARM)

Role
Chief Financial Officer
Signature
/s/ Monica Forbes
Stock symbol
CARM
Transactions as of
Mar 2, 2023
Transactions value $
$14,837
Form type
4
Date filed
3/6/2023, 07:41 PM
Previous filing
Feb 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CARM Common Stock Sale -$90.6K -154K -32.11% $0.59* 326K Mar 2, 2023 Direct F1, F2
transaction CARM Common Stock Options Exercise $112K +190K +58.38% $0.59* 516K Mar 2, 2023 Direct F3
transaction CARM Common Stock Sale -$54.8K -93.3K -18.06% $0.59* 423K Mar 2, 2023 Direct F2, F4
transaction CARM Common Stock Options Exercise $106K +181K +42.71% $0.59* 604K Mar 2, 2023 Direct F5
transaction CARM Common Stock Sale -$57.7K -98.3K -16.28% $0.59* 506K Mar 2, 2023 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2 The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above.
F3 Represents performance-based restricted stock units granted on October 1, 2021, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
F4 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on October 1, 2021. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F5 Represents performance-based restricted stock units granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
F6 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.